Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers

References

• Kitabchi A, Umpierrez G, Miles J, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335–43.
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman A, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163–96.
   PubMed Web of Science ®Google Scholar
• Kenny C. When hypoglycemia is not obvious: diagnosing and treating under-recognized and undisclosed hypoglycemia. Primary Care Diabetes 2014;8:3–11.
   PubMed Web of Science ®Google Scholar
• Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes–systematic overview of prospective observational studies. Diabetologia 2005;48:2460–9.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hu X, Zhang Q, Zou R. Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis. Age Ageing 2016;45:761–7.
   PubMed Web of Science ®Google Scholar
• Chiang JL, Kirkman MS, Laffel LMB, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014;37:2034–54.
   PubMed Web of Science ®Google Scholar
• Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800–11.
   PubMed Web of Science ®Google Scholar
• Haw J, Galaviz K, Straus A, et al. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 2017;177:1808–17.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Scaparrotta A, Olivieri C, et al. Seizures and type 1 diabetes mellitus: current state of knowledge. Eur J Endocrinol 2012;167:749–58.
   PubMed Web of Science ®Google Scholar
• Rosberger D. Diabetic retinopathy: current concepts and emerging therapy. Endocrinol Metab Clin North Am 2013;42:721–45.
   PubMed Web of Science ®Google Scholar
• Polisena J, Tran K, Cimon K, et al. Home telehealth for diabetes management: a systematic review and meta-analysis. Diabetes Obes Metab 2009;11:913–30.
   PubMed Web of Science ®Google Scholar
• MacIsaac R, Jerums G, Ekinci E. Glycemic control as primary prevention for diabetic kidney disease. Adv Chronic Kidney Dis 2018;25:141–8.
   PubMed Web of Science ®Google Scholar
• Arguedas J, Leiva V, Wright J. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev 2013;10:CD008277.
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–53.
   PubMed Web of Science ®Google Scholar
• Laios K, Karamanou M, Saridaki Z, et al. Aretaeus of Cappadocia and the first description of diabetes. Hormones 2012;11:109–13.
   PubMedGoogle Scholar
• Stewart W, Ricci J, Chee E, et al. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med 2007;49:672–9.
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014;174:773–85.
   PubMed Web of Science ®Google Scholar
• Pignone M, Alberts M, Colwell J, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010;33:1395–402.
   PubMed Web of Science ®Google Scholar
• Frachetti K, Goldfine A. Bariatric surgery for diabetes management. Curr Opin Endocrinol Diabetes Obes 2009;16:119–24.
   PubMed Web of Science ®Google Scholar
• Kung Y, Du Y, Huang W, et al. Total synthesis of crystalline bovine insulin. Sci Sin 1965;14:1710–6.
   PubMedGoogle Scholar
• Marglin A, Merrifield R. The synthesis of bovine insulin by the solid phase method. J Am Chem Soc 1966;88:5051–2.
   PubMed Web of Science ®Google Scholar
• Blundell TL, Cutfield JF, Cutfield SM, et al. Atomic positions in rhombohedral 2-zinc insulin crystals. Nature 1971;231:506–11.
   PubMed Web of Science ®Google Scholar
• Serena G, Camhi S, Sturgeon C, et al. The role of gluten in celiac disease and Type 1 diabetes. Nutrients 2015;7:7143–62.
   PubMed Web of Science ®Google Scholar
• Nathan D, Cleary P, Backlund J, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–53.
   PubMed Web of Science ®Google Scholar
• Mottalib A, Kasetty M, Mar J, et al. Weight management in patients with Type 1 diabetes and obesity. Curr Diabetes Rep 2017;17:92.
   PubMed Web of Science ®Google Scholar
• Ripsin C, Kang H, Urban R. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician 2009;79:29–36.
   PubMed Web of Science ®Google Scholar
• Malik V, Popkin B, Bray G, et al. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care 2010;33:2477–83.
   PubMed Web of Science ®Google Scholar
• Emadian A, Andrews R, England C, et al. The effect of macronutrients on glycaemic control: a systematic review of dietary randomised controlled trials in overweight and obese adults with type 2 diabetes in which there was no difference in weight loss between treatment groups. Br J Nutr 2015;114:1656–66.
   PubMed Web of Science ®Google Scholar
• Grams J, Garvey W. Weight loss and the prevention and treatment of Type 2 diabetes using lifestyle therapy, pharmacotherapy, and Bariatric Surgery: mechanisms of action. Curr Obes Rep 2015;4:287–302.
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Strollo R, Bonora E. One size does not fit all glycemic targets for type 2 diabetes. J Diabetes Investig 2014;5:134–41.
   PubMed Web of Science ®Google Scholar
• Krentz A, Bailey C. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385–411.
   PubMed Web of Science ®Google Scholar
• Schulman A, Genio F, Sinha N, et al. "Metabolic" surgery for treatment of type 2 diabetes mellitus. Endocr Pract 2009;15:624–31.
   PubMed Web of Science ®Google Scholar
• Colucci R. Bariatric surgery in patients with type 2 diabetes: a viable option. Postgrad Med 2011;123:24–33.
   PubMed Web of Science ®Google Scholar
• Dixon J, Roux C, Rubino F, et al. Bariatric surgery for type 2 diabetes. Lancet 2012;379:2300–11.
   PubMed Web of Science ®Google Scholar
• Meisinger C, Thorand B, Schneider A, et al. Sex differences in risk factors for incident type 2 Diabetes Mellitus: the MONICA Augsburg Cohort Study. JAMA Intern Med 2002;162:82–9.
   Web of Science ®Google Scholar
• Maria R, Pala L, Mannucci E. Role of insulin in the type 2 diabetes therapy: past, present and future. Int J Endocrinol Metab 2013;11:137–44.
   PubMedGoogle Scholar
• Shapiro S, Parrino V, Freedman L. Hypoglycemic agents. I. Chemical properties of β-phenethylbiguanide. A new hypoglycemic agent. J Am Chem Soc 1959;81:2220–5.
   Web of Science ®Google Scholar
• McKendry J, Kuwayti K, Rado P. Clinical experience with DBI (Phenformin) in the management of diabetes. Can Med Assoc J 1959;80:773–8.
   PubMedGoogle Scholar
• Fimognari F, Corsonello A, Pastorelli R, et al. Older age and phenformin therapy: a dangerous association. Intern Emerg Med 2008;3:401–3.
   PubMed Web of Science ®Google Scholar
• Ching C, Lai C, Poon W, et al. Hazards posed by a banned drug-phenformin is still hanging around. Hong Kong Med J 2008;14:50–4.
   PubMedGoogle Scholar
• Weinberg B, Samuel E, Navdeep S. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol 2015;11:9–15.
   PubMed Web of Science ®Google Scholar
• Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J 2015;471:307–22.
   PubMed Web of Science ®Google Scholar
• Gold M, Alderton C, Zvartau H, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010;30:131–46.
   PubMed Web of Science ®Google Scholar
• Lewis J. Will 2008 mark the start of a new clinical trial era in gastroenterology. Gastroenterology 2008;134:1289.
   PubMed Web of Science ®Google Scholar
• Cantello BCC, Cawthorne MA, Haigh D, et al. The synthesis of BRL 49653 – a novel and potent antihyperglycaemic agent. Bioorganic 1994;4:1181–4.
   Web of Science ®Google Scholar
• Scheen A. Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract 2012;98:175–86.
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison S, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297–307.
   PubMed Web of Science ®Google Scholar
• Filipova E, Uzunova K, Kalinov K, et al. Pioglitazone and the risk of bladder cancer: a meta-analysis. Diabetes Ther 2017;8:705–26.
   PubMed Web of Science ®Google Scholar
• Colca J, McDonald W, Waldon D, et al. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 2004;286:E252–60.
   PubMed Web of Science ®Google Scholar
• Colle R, Larminat D, Rotenberg S, et al. Pioglitazone could induce remission in major depression: a meta-analysis. Neuropsychiatr Dis Treat 2017;13:9–16.
   PubMed Web of Science ®Google Scholar
• Doyle C, McDougle C. Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opin Pharmacother 2012;13:1615–29.
   PubMed Web of Science ®Google Scholar
• Berger J, Moller D. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409–35.
   PubMed Web of Science ®Google Scholar
• Dreyer C, Krey G, Keller H, et al. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992;68:879–87.
   PubMed Web of Science ®Google Scholar
• Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645–50.
   PubMed Web of Science ®Google Scholar
• Meirhaeghe A, Amouyel P. Impact of genetic variation of PPARgamma in humans. Mol Genet Metab 2004;83:93–102.
   PubMed Web of Science ®Google Scholar
• Zoete V, Grosdidier A, Michielin O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 2007;1771:915–25.
   PubMed Web of Science ®Google Scholar
• Chittiboyina A, Venkatraman M, Mizuno C, et al. Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists. J Med Chem 2006;49:4072–84.
   PubMed Web of Science ®Google Scholar
• Madhavan G, Chakrabarti R, Vikramadithyan R, et al. Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives. Biol Med Chem 2002;10:2671–80.
   PubMed Web of Science ®Google Scholar
• Atanasov A, Wang J, Kramer M, et al. Honokiol: a non-adipogenic PPARγ agonist from nature. Biochim Biophys Acta 2013;1830:4813–9.
   PubMed Web of Science ®Google Scholar
• Li Z, Liao C, Ko B, et al. Design, synthesis, and evaluation of a new class of noncyclic 1, 3-dicarbonyl compounds as PPARα selective activators. Biol Med Chem Lett 2004;14:3507–11.
   PubMed Web of Science ®Google Scholar